Clinical Rheumatology - Editor highlights - November 2021

Prof. Carlos Pineda provides his Editor-in-Chief highlights from this issue; where the article is not already Open Access, the read-only version of each article has been made available.

The issue can be found in full on SpringerLink (this opens in a new tab).

Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis (this opens in a new tab)  (this opens in a new tab)Fleischmann, R.

Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study (this opens in a new tab) Lorenzin, M, Ortolan, A, Cozzi, G et al.

Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis—a systematic review and meta-analysis (this opens in a new tab) Misra, DP, Rathore, U, Patro, P et al.